Prelude Therapeutics Incorporated
PRLD
$1.27
$0.032.42%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.26% | -1.82% | -4.38% | -12.03% | -11.23% |
| Total Depreciation and Amortization | 18.41% | 35.23% | 51.58% | 34.50% | 18.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -17.53% | -18.35% | -24.01% | -16.97% | -23.77% |
| Change in Net Operating Assets | -176.18% | 137.72% | 140.23% | 124.39% | 128.75% |
| Cash from Operations | -4.07% | 3.12% | 3.90% | 0.65% | -2.91% |
| Capital Expenditure | 92.27% | 82.55% | 78.25% | 33.74% | 23.66% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.40% | 760.15% | 392.15% | 303.00% | 363.01% |
| Cash from Investing | 33.00% | 665.52% | 360.32% | 284.78% | 332.47% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -428.13% | -- | -- | -- | -- |
| Issuance of Common Stock | -98.94% | -99.68% | -99.68% | -77.05% | -77.01% |
| Repurchase of Common Stock | 47.06% | -30.30% | -217.65% | -200.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 69.05% | -137.04% | -- | -- | -- |
| Cash from Financing | -101.14% | -100.19% | -100.09% | -77.41% | -77.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -250.22% | 139.19% | -141.19% | 86.82% | 105.70% |